| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| Abcc6 | Ahsg | ENSRNOP00000051412 | ENSRNOP00000073898 | Multidrug resistance-associated protein 6; May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. | Alpha-2-HS-glycoprotein; Could inhibit both insulin-receptor tyrosine kinase activity and insulin-stimulated receptor autophosphorylation and, concomitantly, antagonize the mitogenic effect of the hormone in cultured rat hepatoma cells. | 0.598 |
| Abcc6 | Ggcx | ENSRNOP00000051412 | ENSRNOP00000017928 | Multidrug resistance-associated protein 6; May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. | Vitamin K-dependent gamma-carboxylase; Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide. | 0.797 |
| Abcc6 | Mgp | ENSRNOP00000051412 | ENSRNOP00000007577 | Multidrug resistance-associated protein 6; May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. | Matrix Gla protein; Associates with the organic matrix of bone and cartilage. Thought to act as an inhibitor of bone formation. | 0.722 |
| Abcc6 | Vkorc1 | ENSRNOP00000051412 | ENSRNOP00000063977 | Multidrug resistance-associated protein 6; May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. | Vitamin K epoxide reductase complex subunit 1; Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. | 0.608 |
| Ahsg | Abcc6 | ENSRNOP00000073898 | ENSRNOP00000051412 | Alpha-2-HS-glycoprotein; Could inhibit both insulin-receptor tyrosine kinase activity and insulin-stimulated receptor autophosphorylation and, concomitantly, antagonize the mitogenic effect of the hormone in cultured rat hepatoma cells. | Multidrug resistance-associated protein 6; May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. | 0.598 |
| Ahsg | Bglap | ENSRNOP00000073898 | ENSRNOP00000026530 | Alpha-2-HS-glycoprotein; Could inhibit both insulin-receptor tyrosine kinase activity and insulin-stimulated receptor autophosphorylation and, concomitantly, antagonize the mitogenic effect of the hormone in cultured rat hepatoma cells. | Osteocalcin; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium. | 0.631 |
| Ahsg | Bmp2 | ENSRNOP00000073898 | ENSRNOP00000028904 | Alpha-2-HS-glycoprotein; Could inhibit both insulin-receptor tyrosine kinase activity and insulin-stimulated receptor autophosphorylation and, concomitantly, antagonize the mitogenic effect of the hormone in cultured rat hepatoma cells. | Bone morphogenetic protein 2; Induces cartilage and bone formation. Stimulates the differentiation of myoblasts into osteoblasts via the EIF2AK3-EIF2A- ATF4 pathway. BMP2 activation of EIF2AK3 stimulates phosphorylation of EIF2A which leads to increased expression of ATF4 which plays a central role in osteoblast differentiation. In addition stimulates TMEM119, which upregulates the expression of ATF4. Belongs to the TGF-beta family. | 0.423 |
| Ahsg | Mgp | ENSRNOP00000073898 | ENSRNOP00000007577 | Alpha-2-HS-glycoprotein; Could inhibit both insulin-receptor tyrosine kinase activity and insulin-stimulated receptor autophosphorylation and, concomitantly, antagonize the mitogenic effect of the hormone in cultured rat hepatoma cells. | Matrix Gla protein; Associates with the organic matrix of bone and cartilage. Thought to act as an inhibitor of bone formation. | 0.832 |
| Ahsg | Runx2 | ENSRNOP00000073898 | ENSRNOP00000057733 | Alpha-2-HS-glycoprotein; Could inhibit both insulin-receptor tyrosine kinase activity and insulin-stimulated receptor autophosphorylation and, concomitantly, antagonize the mitogenic effect of the hormone in cultured rat hepatoma cells. | Runt-related transcription factor 2; Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. Inhibits KAT6B-dependent transcriptional activation. In osteoblasts, supports transcription activati [...] | 0.554 |
| Ahsg | Spp1 | ENSRNOP00000073898 | ENSRNOP00000062358 | Alpha-2-HS-glycoprotein; Could inhibit both insulin-receptor tyrosine kinase activity and insulin-stimulated receptor autophosphorylation and, concomitantly, antagonize the mitogenic effect of the hormone in cultured rat hepatoma cells. | Osteopontin; Binds tightly to hydroxyapatite. Appears to form an integral part of the mineralized matrix. Probably important to cell-matrix interaction; Belongs to the osteopontin family. | 0.631 |
| Ahsg | Ucma | ENSRNOP00000073898 | ENSRNOP00000063022 | Alpha-2-HS-glycoprotein; Could inhibit both insulin-receptor tyrosine kinase activity and insulin-stimulated receptor autophosphorylation and, concomitantly, antagonize the mitogenic effect of the hormone in cultured rat hepatoma cells. | Unique cartilage matrix-associated protein C-terminal fragment; May be involved in the negative control of osteogenic differentiation of osteochondrogenic precursor cells in peripheral zones of fetal cartilage and at the cartilage-bone interface. | 0.554 |
| Bglap | Ahsg | ENSRNOP00000026530 | ENSRNOP00000073898 | Osteocalcin; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium. | Alpha-2-HS-glycoprotein; Could inhibit both insulin-receptor tyrosine kinase activity and insulin-stimulated receptor autophosphorylation and, concomitantly, antagonize the mitogenic effect of the hormone in cultured rat hepatoma cells. | 0.631 |
| Bglap | Bmp2 | ENSRNOP00000026530 | ENSRNOP00000028904 | Osteocalcin; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium. | Bone morphogenetic protein 2; Induces cartilage and bone formation. Stimulates the differentiation of myoblasts into osteoblasts via the EIF2AK3-EIF2A- ATF4 pathway. BMP2 activation of EIF2AK3 stimulates phosphorylation of EIF2A which leads to increased expression of ATF4 which plays a central role in osteoblast differentiation. In addition stimulates TMEM119, which upregulates the expression of ATF4. Belongs to the TGF-beta family. | 0.884 |
| Bglap | Dcn | ENSRNOP00000026530 | ENSRNOP00000006070 | Osteocalcin; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium. | Decorin; May affect the rate of fibrils formation (By similarity). May be implicated in the dilatation of the rat cervix. | 0.509 |
| Bglap | Ggcx | ENSRNOP00000026530 | ENSRNOP00000017928 | Osteocalcin; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium. | Vitamin K-dependent gamma-carboxylase; Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide. | 0.982 |
| Bglap | Mgp | ENSRNOP00000026530 | ENSRNOP00000007577 | Osteocalcin; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium. | Matrix Gla protein; Associates with the organic matrix of bone and cartilage. Thought to act as an inhibitor of bone formation. | 0.810 |
| Bglap | Runx2 | ENSRNOP00000026530 | ENSRNOP00000057733 | Osteocalcin; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium. | Runt-related transcription factor 2; Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. Inhibits KAT6B-dependent transcriptional activation. In osteoblasts, supports transcription activati [...] | 0.978 |
| Bglap | Spp1 | ENSRNOP00000026530 | ENSRNOP00000062358 | Osteocalcin; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium. | Osteopontin; Binds tightly to hydroxyapatite. Appears to form an integral part of the mineralized matrix. Probably important to cell-matrix interaction; Belongs to the osteopontin family. | 0.931 |
| Bglap | Ucma | ENSRNOP00000026530 | ENSRNOP00000063022 | Osteocalcin; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium. | Unique cartilage matrix-associated protein C-terminal fragment; May be involved in the negative control of osteogenic differentiation of osteochondrogenic precursor cells in peripheral zones of fetal cartilage and at the cartilage-bone interface. | 0.558 |
| Bglap | Vkorc1 | ENSRNOP00000026530 | ENSRNOP00000063977 | Osteocalcin; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium. | Vitamin K epoxide reductase complex subunit 1; Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. | 0.420 |